Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41587-021-00824-8 | DOI Listing |
Publication Analysis
Top Keywords
trop2 deal
4
deal heats
4
heats antibody-drug
4
antibody-drug conjugate
4
conjugate space
4
space cancer
4
trop2
1
heats
1
antibody-drug
1
conjugate
1
Similar Publications
Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort.
Mol Diagn Ther
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany.
Article Synopsis
- Salivary gland carcinomas (SGC) are diverse with 24 subtypes, primarily treated through surgery and radiotherapy, but have a low 5-year survival rate of 20% for patients with recurrence or metastasis.
- A study involving 55 SGC patients investigated various druggable molecular alterations using immunohistochemical staining and fluorescence in situ hybridization, finding a 54.4% prevalence of such alterations, with EGFR overexpression being the most common.
- Targeted therapies like trastuzumab deruxtecan and pembrolizumab may offer new treatment options for patients with RM-SGC who cannot undergo salvage surgery.
Trop2 deal heats up antibody-drug conjugate space in cancer.
Nat Biotechnol
February 2021
, Ann Arbor, MI, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!